Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Illumina reorganises to help focus on molecular diagnostics development

Illumina : 07 January, 2008  (New Product)
llumina has reorganised the company’s operating structure to improve the synergies between its sequencing and genotyping businesses.
Under the new structure, a newly created Life Sciences Business Unit will include all products and services related to the research market namely the BeadArray, BeadXpress and Sequencing product lines. The company has also created a Diagnostics Business Unit to put more focus on the emerging opportunity in molecular diagnostics.

The Diagnostics Business Unit will develop diagnostic content for the BeadXpress system, and ultimately for Illumina’s Sequencing products.
“Over the last few years we have experienced incredible growth. This new organizational structure provides the foundation to continue scaling our global operations and more effectively leverage our technology assets to capitalise on future opportunities. A specific result will be the acceleration of the integration of our sequencing and genotyping technologies. Additionally, it will enable us to put more focus on developing our diagnostics business,” said Jay Flatley, president and chief executive officer of Illumina.

The timing of this reorganisation was driven by several management changes. John Stuelpnagel, senior vice president, chief operating officer and general manager, Arrays has decided to move to part-time status as of April 1, 2008. Dr Stuelpnagel is expected to have a continuing role with the company working on key projects as an Illumina Fellow. Additionally, he will step down from Illumina’s Board of Directors as of that date.

“John has spent the last ten years founding, building and leading Illumina into a pre-eminent life sciences company. Although we are disappointed that John has decided to step down from his full time role, we expect to continue to benefit from his broad experience, leadership and vision,” said Flatley.

John West, senior vice president and general manager, Sequencing has announced his resignation effective February 1, 2008. “As the former CEO of Solexa, John has been instrumental in building the next generation sequencing market and facilitating the integration of Solexa into Illumina. We thank John for his outstanding contributions to Solexa and Illumina and wish him well in his future endeavours,” Flatley said.

Effective immediately, Christian Henry, senior vice president and chief financial officer will take on the role of acting general manager of the Sequencing business. In addition to his other duties, Henry’s primary goal will be to effectively manage the integration of the Sequencing business into the new combined Life Sciences Business Unit. The integration is expected to be completed before the end of the second quarter.

“We expect to integrate all product development activities from the array and sequencing businesses under the Senior Vice President Product Development. Similarly, all manufacturing and materials activities will be integrated under the Senior Vice President Operations. We will continue to operate in all our existing development and manufacturing locations, namely San Diego, Hayward and Little Chesterford, UK,” continued Flatley.

“To keep pace with our rapid growth, Illumina’s infrastructure has matured significantly over the last several years. Our new organizational structure is a required evolution on the path toward our goal of becoming the global leader in genetic analysis. I look forward to an exciting 2008 for Illumina.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo